REPORT ID 4814

EMEA (Europe, Middle East and Africa) Hypoxia Inducible Factor 1 Alpha Inhibitor Market Report 2017

Publish Date
19-Dec-17
Pages
114
Format
Electronic (PDF)

In this report, the EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Hypoxia Inducible Factor 1 Alpha Inhibitor for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor market competition by top manufacturers/players, with Hypoxia Inducible Factor 1 Alpha Inhibitor sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Aileron Therapeutics, Inc.
    CASI Pharmaceuticals Inc.
    Cerulean Pharma, Inc.
    F. Hoffmann-La Roche Ltd.
    InterMed Discovery GmbH
    OncoImmune, Inc.
    Peloton Therapeutics, Inc.
    RXi Pharmaceuticals Corporation
    Sorrento Therapeutics, Inc.
    Transcriptogen Ltd
    Vascular Biogenics Ltd.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    BC-001
    CASI-2ME2
    CRLX-101
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Solid Tumor
    Acute Myelocytic Leukemia
    Colorectal Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Hypoxia Inducible Factor 1 Alpha Inhibitor Market Report 2017
1 Hypoxia Inducible Factor 1 Alpha Inhibitor Overview
    1.1 Product Overview and Scope of Hypoxia Inducible Factor 1 Alpha Inhibitor
    1.2 Classification of Hypoxia Inducible Factor 1 Alpha Inhibitor
        1.2.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 BC-001
        1.2.4 CASI-2ME2
        1.2.5 CRLX-101
        1.2.6 Others
    1.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Application/End Users
        1.3.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Solid Tumor
        1.3.3 Acute Myelocytic Leukemia
        1.3.4 Colorectal Cancer
        1.3.5 Others
    1.4 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Region
        1.4.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Hypoxia Inducible Factor 1 Alpha Inhibitor (2012-2022)
        1.5.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Growth Rate (2012-2022)

2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market Competition by Players/Manufacturers
        2.1.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sale Price by Players (2012-2017)
    2.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume and Value) by Type/Product Category
        2.2.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sale Price by Type (2012-2017)
    2.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume) by Application
    2.4 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume and Value) by Region
        2.4.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Price by Region (2012-2017)

3 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Value (2012-2017)
        3.1.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Growth Rate (2012-2017)
    3.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Type
    3.3 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Application
    3.4 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume by Countries (2012-2017)
        3.4.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Countries (2012-2017)
        3.4.3 Germany Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        3.4.4 France Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        3.4.5 UK Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        3.4.6 Russia Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        3.4.7 Italy Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)

4 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Value (2012-2017)
        4.1.1 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Growth Rate (2012-2017)
    4.2 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Type
    4.3 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Application
    4.4 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        4.4.4 Israel Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        4.4.5 UAE Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        4.4.6 Iran Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)

5 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Value (2012-2017)
        5.1.1 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Growth Rate (2012-2017)
    5.2 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Type
    5.3 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Market Share by Application
    5.4 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Volume by Countries (2012-2017)
        5.4.2 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Countries (2012-2017)
        5.4.3 South Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate (2012-2017)

6 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Manufacturers/Players Profiles and Sales Data
    6.1 Aileron Therapeutics, Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Aileron Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 CASI Pharmaceuticals Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 CASI Pharmaceuticals Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Cerulean Pharma, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Cerulean Pharma, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 F. Hoffmann-La Roche Ltd.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 F. Hoffmann-La Roche Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 InterMed Discovery GmbH
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 InterMed Discovery GmbH Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 OncoImmune, Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 OncoImmune, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Peloton Therapeutics, Inc.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Peloton Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 RXi Pharmaceuticals Corporation
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 RXi Pharmaceuticals Corporation Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sorrento Therapeutics, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sorrento Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Transcriptogen Ltd
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Transcriptogen Ltd Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Vascular Biogenics Ltd.

7 Hypoxia Inducible Factor 1 Alpha Inhibitor Manufacturing Cost Analysis
    7.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Hypoxia Inducible Factor 1 Alpha Inhibitor

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Hypoxia Inducible Factor 1 Alpha Inhibitor Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Market Forecast (2017-2022)
    11.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Price and Trend Forecast (2017-2022)
    11.2 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Forecast by Type (2017-2022)
    11.7 EMEA Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources